Impact of multiple sclerosis disease-modifying therapies on SARS-CoV-2 vaccine-induced antibody and T cell immunity
Preprint
Abstract
Vaccine-elicited adaptive immunity is an essential prerequisite for effective prevention and control of coronavirus 19 (COVID-19). Treatment of multiple sclerosis (MS) involves a diverse array of disease-modifying therapies (DMTs) that target antibody and cell-mediated immunity, yet a comprehensive understanding of how MS DMTs impact SARS-CoV-2 vaccine responses is lacking. We completed a detailed analysis of SARS-CoV-2 vaccine-elicited spike antigen-specific IgG and T cell responses in a cohort of healthy controls and MS participants in six different treatment categories. Two specific DMT types, sphingosine-1-phosphate (S1P) receptor modulators and anti-CD20 monoclonal antibodies (mAb), resulted in significantly reduced spike-specific IgG responses. Longer duration of anti-CD20 mAb treatment prior to SARS-CoV-2 vaccination were associated with absent antibody responses. Except for reduced CD4+ T cell responses in S1P-treated patients, spike-specific CD4+ and CD8+ T cell reactivity remained robust across all MS treatment types. These findings have important implications for clinical practice guidelines and vaccination recommendations in MS patients and other immunosuppressed populations.Keywords
All Related Versions
- Published version: JCI Insight, 7 (4).
This publication has 39 references indexed in Scilit:
- Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed IndividualsCell, 2020
- Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable TherapiesJAMA Neurology, 2020
- Anti-CD20 therapy depletes activated myelin-specific CD8+T cells in multiple sclerosisProceedings of the National Academy of Sciences, 2019
- Immunological Aspects of Approved MS TherapeuticsFrontiers in Immunology, 2019
- Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune diseaseProceedings of the National Academy of Sciences, 2018
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteriaThe Lancet Neurology, 2018
- Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosisNature, 2011
- Tracking epitope-specific T cellsNature Protocols, 2009
- FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosisNeurology, 2008
- Generation of peptide–MHC class I complexes through UV-mediated ligand exchangeNature Protocols, 2006